m6A levels and expression of its modification genes show significant differences in breast cancer molecular subtypes
作者机构：BIOMICs Research GroupLascaray Research CenterUniversity of the Basque Country UPV/EHUVitoria-GasteizAraba 01006Spain Bioaraba Health Research InstituteVitoria-GasteizAraba 01009Spain Department of Biochemistry and Molecular BiologyUniversity of the Basque CountryUPV/EHUVitoria-GasteizAraba 01006Spain Molecular Genetics LaboratoryAraba University HospitalOsakidetza Basque Health ServiceVitoria-GasteizAraba 01009Spain Pathology DepartmentAraba University HospitalVitoria-GasteizAraba 01009Spain Department of GeneticsPhysical Anthropology and Animal PhysiologyUniversity of the Basque Country(UPV/EHU)LeioaBizkaia 48940Spain BioCruces Bizkaia Health Research InstituteBarakaldoBizkaia 48903Spain Department of Zoology and Animal Biology.University of the Basque Country(UPV/EHU)LeioaBizkaia 48940Spain
出 版 物：《Genes & Diseases》 (基因与疾病（英文）)
年 卷 期：2023年第10卷第5期
页 面：1751-1754页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：supported by the Basque Government Spain(IT1633-22 and predoctoral fellowship PRE_2019_2_0005 to TK)
摘 要：N6-methyladenosine(m6A)is the most abundant modification in eukaryotic messenger RNA.1 This modification is dynamic,reversible,and mediated by proteins characterized as methyltransferases and *** investigations have found that aberrant expression of methyltransferases and demethylases results in m6A dysregulation and,in consequence,affects the biological functions in which this modification is ***,m6A dysregulation affects the development and maintenance of various diseases,including cancer.2 For this reason,we explored the potential role that m6A modification has in invasive breast cancer of no special type(IBC-NST)and its molecular subtypes luminal A,luminal B HER2-,luminal B HER2+,HER2+,and triple-negative breast cancer(TNBC)whose degree of global m6A methylation has not yet been studied.
维普期刊数据库